RECRUITING

Home Exercise for Individuals With Neurodegenerative Disease

Conditions

Neurodegenerative Diseases Leukodystrophy Ataxia LBSL Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation Cerebellar Ataxia Adrenomyeloneuropathy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.

Official Title

Study of Adapted Exercise and Mindfulness Interventions to Improve Motor Function and Sleep Quality in Individuals With Neurodegenerative Disease

Quick Facts

Study Start:2023-02-13

Study Completion:2027-07-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05443906

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing. * The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis. * The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis. * For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia. * We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam. * Able to stand for 30 seconds without upper extremity support * Ambulatory (including use of a cane or a walker) * Able to walk for 2 minutes	* Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:

Inclusion Criteria

Exclusion Criteria

* The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.
* The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.
* The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.
* For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.
* We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.
* Able to stand for 30 seconds without upper extremity support
* Ambulatory (including use of a cane or a walker)
* Able to walk for 2 minutes

* Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:

Contacts and Locations

Study Contact

Dandre Amos, BS

CONTACT

443-923-2769

amosd@kennedykrieger.org

Amena Smith Fine, MD PhD

CONTACT

443-923-3249

finea@kennedykrieger.org

Principal Investigator

Jennifer Keller, PT

PRINCIPAL_INVESTIGATOR

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Study Locations (Sites)

Kennedy Krieger Institute

Baltimore, Maryland, 21205

United States

Collaborators and Investigators

Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Jennifer Keller, PT, PRINCIPAL_INVESTIGATOR, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-13

Study Completion Date2027-07-30

Study Record Updates

Study Start Date2023-02-13

Study Completion Date2027-07-30

Terms related to this study

Additional Relevant MeSH Terms

Neurodegenerative Diseases
Leukodystrophy
Ataxia
LBSL
Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)
Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation
Cerebellar Ataxia
Adrenomyeloneuropathy